Navigation Links
Hospira Highlights Strategic Initiatives at Its 2008 Annual Meeting of Shareholders
Date:5/13/2008

- Shareholders Ratify Both Proposals -

LAKE FOREST, Ill., May 13 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today held its 2008 Annual Meeting of Shareholders in Wilmington, Del. The agenda included votes on two proposals and a brief update on the company's progress and strategy.

"Our 2007 results point to the success of our strategies of investing for growth, and improving operating margins and cash flow," said Christopher B. Begley, chairman and chief executive officer, Hospira. "It's through our disciplined focus on executing these strategies that Hospira has become the growing, profitable company it is today and is positioned for continued success going forward."

During the annual meeting, shareholders:

-- elected the following directors for three-year terms expiring in 2011:

Irving W. Bailey, II, Ronald A. Matricaria and

Jacque J. Sokolov, M.D.; and

-- ratified the appointment of Deloitte & Touche LLP as Hospira's auditors

for 2008.

A full description of the above matters was included in Hospira's proxy statement related to the meeting. The proxy statement is available on Hospira's Web site at http://www.hospirainvestor.com, as are Begley's remarks made at today's meeting.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.
Private Securities Litigation Reform Act of 1995 -- A Caution Concerning

Forward-Looking Statements This press release contains statements that may be construed as forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and the subsequent Form 10-Q, filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira to Present at the Bank of America 2008 Health Care Conference on May 14
2. Hospira Acquires Sculptor
3. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
4. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
5. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
6. Hospira Launches Generic Irinotecan Injection
7. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
8. Hospira Hosts Conference Call for Fourth-Quarter 2007 Results and 2008 Projections
9. Hospira to Present at the JPMorgan 26th Annual Healthcare Conference on January 9
10. Hospira Reports Third-Quarter 2007 Results
11. Hospira to Present at the Credit Suisse Phoenix Health Care Conference on November 13
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... Plainsboro, NJ (PRWEB) , ... December 08, 2016 , ... ... patients, cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts ... In making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Premier Fitness Camp ... FIT , the ultimate weight loss and wellness program, at their world headquarters of ... to provide immediate and long-term results to anyone seeking weight loss, personal development, a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) ... per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks ... (WCRI) . , According to the study, medical payments per claim in California decreased ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Research and Markets has announced the addition of ... report to their offering. ... The report also analyses the market by the following Technology Types: Label-Free ... the US, Canada , Japan , ... Latin America , and Rest of World. Annual ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a ... to address severe, rare diseases, today announced that senior management will ... Success Healthcare Conference at the InterContinental Barclay Hotel in ... 4:20 p.m. ET. About aTyr Pharma ... aTyr Pharma is engaged ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, Inc. ... (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to ... for the treatment of bacterial infections including those ... recognized as an attractive antibacterial target for more ... of suitable chemical starting points has hampered its ...
Breaking Medicine Technology: